Equities

LIDDS

SE0001958612

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:54:20 2024-05-06 am EDT			5-day change	1st Jan Change
0.173 ^SEK	+4.22%		+6.13%	+60.19%

Mar. 21	Sweden's Lidds Finalizes Purchase of Noviga Research	MT
Mar. 21	LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	CI

Max Mitteregger Resigns from the LIDDS's Board

July 02, 2023 at 04:40 pm EDT

LIDDS announced that Max Mitteregger will leave the board of directors of LIDDS. The company's board thus consists of Pontus Ottosson (chairman), David Bejker, Daniel Lifveredson and Johan Lund. Max Mitteregger's resignation is at his own request.

Latest news about LIDDS AB

Sweden's Lidds Finalizes Purchase of Noviga Research	Mar. 21	MT
LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	Mar. 20	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
LIDDS AB (OM:LIDDS) signed an agreement to acquire Noviga Research AB.	Jan. 28	CI
LIDDS AB Approves Board Elections	Jan. 09	CI
Lidds AB Announces Resignation of Daniel Lifveredson from Board of Directors	Dec. 07	CI
Lidds CFO to Take Over CEO Role; Shares Plunge	Nov. 28	MT
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
LIDDS AB Announces CEO Changes	Nov. 28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
LIDDS AB Announces CEO Changes	23-07-31	CI
LIDDS AB Announces Closure of R&D Project with Johnson & Johnson Enterprise Innovation Inc	23-07-06	CI
Max Mitteregger Resigns from the LIDDS's Board	23-07-02	CI
Anders MÃ¥nsson Plans to Leave the LIDDS AB as CEO	23-06-27	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
LIDDS AB Announces Management Changes	23-03-13	CI
LIDDS AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-13	CI
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
LIDDS AB Announces CEO Changes	22-07-15	CI
LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel	22-07-08	CI
LIDDS AB Appoint Executives	22-07-07	CI
Sweden's Lidds Obtains Patent for Drug Release Technology in Japan, South Korea	22-06-07	MT
LIDDS AB Announces Board Changes	22-06-01	CI

Chart LIDDS AB

Duration

Period

More charts

Company Profile

Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Companyâs portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIDDS AB	+60.19%	2.1M
REGENERON PHARMACEUTICALS, INC.	+8.56%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-0.88%	104B
ARGENX SE	+5.79%	22.94B
BIONTECH SE	-12.60%	22.34B
GENMAB A/S	-7.01%	19.25B
WUXI APPTEC CO., LTD.	-37.08%	17.08B
BEIGENE, LTD.	-9.28%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+7.98%	14.16B
SAREPTA THERAPEUTICS, INC.	+39.09%	12.63B

Bio Therapeutic Drugs